"Nefecon","Ambrisentan"
ApprovedSmall molecule
"Nefecon","Ambrisentan" is one of 35 small molecule programs targeting IgA Nephropathy. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
99 competitors in Iga Nephropathy
#DrugCompanyPhaseTrials
1Avapro
SanofiPhase 3
Kerendia
BayerPhase 3
Farxiga
AstraZenecaPhase 3
Filspari
TTravere Therapeutics, Inc.
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
LNP023
NovartisPhase 3
Medrol
PfizerPhase 2
Telitacicept
VVor Biopharma
Phase 3
Mezagitamab
TakedaPhase 3
Atacicept
EMD SeronoPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for "Nefecon","Ambrisentan". EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details